000 03725nam a22004575i 4500
001 978-3-030-99995-7
003 DE-He213
005 20240729133802.0
007 cr nn 008mamaa
008 220721s2022 sz | s |||| 0|eng d
020 _a9783030999957
_9978-3-030-99995-7
024 7 _a10.1007/978-3-030-99995-7
_2doi
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
072 7 _aMKG
_2thema
245 1 0 _aFrom Obesity to Diabetes
250 _a1st ed. 2022.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2022.
300 _aVIII, 513 p. 1 illus.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aHandbook of Experimental Pharmacology,
_x1865-0325 ;
_v274
505 0 _aPart I Obesity. Epidemiology of Obesity -- The Circadian Clock and Obesity -- Nutrition and Microbiome -- From Obesity to Diabetes: The Role of the Adipose Organ -- Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy -- The Enteroendocrine System in Obesity -- Insights from Studies of White Adipose Tissue Using Single-Cell Approaches -- Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction -- Obesity, Senescence, and Senolytics -- Obesity and Obstructive Sleep Apnea -- Part II Diabetes and Complications. Inter-Organ Crosstalk in the Development of Obesity-Associated Insulin Resistance -- Islet Inflammation and β Cell Dysfunction in Type 2 Diabetes -- NAFLD and NASH: The Metabolically Diseased Liver -- Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities -- Diabetic Peripheral Neuropathy -- Part III Lifestyle Modifications and Future Treatments. Weight Loss Strategies -- PhysicalActivity, Obesity and Weight Loss Maintenance -- Bariatric/Metabolic Surgery -- Drugs for Treating Obesity -- Novel Drugs for Diabetes Therapy -- Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function -- Precision Medicine and Obesity -- Targeting the Enteroendocrine System for Treatment of Obesity.
520 _aObesity is a major risk factor for the development of type 2 diabetes and its associated complications, a major socio-economic burden for health care systems. The worldwide prevalence of obesity doubled since 1980 and as a consequence the number of patients with diabetes has been continuously rising with more than 450 Mio. people suffering from this disease at the present time. Substantial progress has been made in understanding the molecular pathways leading from excessive fat accumulation to metabolic perturbation and finally diabetes manifestation. This edition of the "Handbook of Experimental Pharmacology" aims to analyze new insight into the pathophysiology of obesity, to decipher the complex links to diabetes and its complications, and to collect most recent information on new strategies for prevention and treatment of obesity and diabetes.
650 0 _aPharmacology.
_97400
650 0 _aMetabolism
_xDisorders.
650 1 4 _aPharmacology.
_97400
650 2 4 _aMetabolic Disease.
700 1 _aEckel, Juergen.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aCl�ment, Karine.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
830 0 _aHandbook of Experimental Pharmacology,
_x1865-0325 ;
_v274
856 _u#gotoholdings
_yAccess resource
912 _aZDB-2-SBL
912 _aZDB-2-SXB
245 _h[E-Book]
999 _c100783
_d100783